ARTICLE | Clinical News
ALX-0171: Ph IIb RESPIRE started
January 13, 2017 4:14 PM UTC
Ablynx began the double-blind, placebo-controlled, international Phase IIb RESPIRE trial to evaluate 3, 6 and 9 mg/kg inhaled ALX-0171 once daily for 3 days in about 180 hospitalized infants ages 1-24...
BCIQ Company Profiles
BCIQ Target Profiles